VivoSim Labs (FRA:4OR) Tariff Resilience Score: 6/10 (As of Jun. 25, 2026)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.39
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Tariff Resilience Score?

VivoSim Labs FRA:4OR 39 Tariff Resilience Score is 6 as of Jun. 25, 2026. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.39. The stock has 4 warning signs investors should review. Among 1,379 Biotechnology companies, VivoSim Labs ranks better than 75.92% on this metric.

VivoSim Labs has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

VivoSim Labs has VivoSim Labs' software-centric business model reduces direct tariff exposure, but hardware dependencies for simulations pose risks. Global client base offers diversification. Historical impacts have been minimal, and the company can leverage alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes VivoSim Labs might have Average Resilient.

VivoSim Labs  (FRA:4OR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

VivoSim Labs Tariff Resilience Score Related Terms

FRA:4OR vs AZTR, GRI, BIXT: Tariff Resilience Score Comparison

For the Biotechnology subindustry, VivoSim Labs's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VivoSim Labs Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Tariff Resilience Score falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
VivoSim Labs (FRA:4OR) has a Tariff Resilience Score of 6 as of Jun. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, VivoSim Labs ranks #332 out of 1379 companies in the Biotechnology industry, placing it in the top 24.1%.
Is VivoSim Labs' Tariff Resilience Score too high?
VivoSim Labs' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. VivoSim Labs' value of 6 is 50% above this industry median. Based on the distribution chart, VivoSim Labs ranks #332 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Tariff Resilience Score compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #332 out of 1379 companies for Tariff Resilience Score. This places VivoSim Labs in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. VivoSim Labs' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €8.39, compared to a current price of €3.49 — trading 58.4% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Tariff Resilience Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 58.4% below its estimated GF Value™ of €8.39.

Key valuation signals for FRA:4OR:

  • Tariff Resilience Score: 6
  • GF Value™: €8.39 vs. price of €3.49 (58.4% below fair value)
  • GF Score™: 39/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#332 of 1379)

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.39
GF Value